dosing. The median time on treatment was 58 days. X-82 blood pharmacokinetics appeared dose-independent with a t 1/2 of 5.13 hours and 6.48 hours for capsule and tablet formulations, respectively. No apparent accumulation was observed after 21 days of daily dosing. Conclusion. X-82 had a safety profile consistent with its mechanism of action. It has a short half-life and was well tolerated by most patients. Study enrollment ended prior to the determination of the MTD because of the apparent saturation of absorption at 400-800 mg. The recommended dose of X-82 as a single agent in patients with advanced cancer is 400 mg q.d. The Oncologist 2019;24:455-e121
DISCUSSION
The study planned to determine the MTD and preliminary pharmacokinetic (PK) characteristics of X-82, administered as a single agent in a continuous daily dosing schedule, in patients with advanced solid tumors. The study began with a capsule formulation of X-82. To improve the absorption and exposure of X-82, a tablet formulation was available with protocol Amendment 3, and patients receiving capsules had the option to switch to the tablet formulation based on availability.
Patients on cohorts 1-6 received 20-400 mg once-daily capsule dosing and patients on cohorts 7 and 8 received 140-200 mg twice-daily capsule dosing. Patients on cohorts 9-17 received 50-800 mg once-daily tablet dosing. Patients were enrolled sequentially into these cohorts. No doselimiting toxicities were observed in the dose levels explored. However, enrollment was stopped prior to determination of the MTD because of the apparent saturation of absorption at 400-800 mg. The recommended dose of X-82 monotherapy in patients with advanced cancer is 400 mg once daily.
To achieve the PK/pharmacodynamic (PD) model reported by Mendel et al., X-82 was designed to have a short t 1/2 and no accumulation in humans. The PK results underscore that our X-82 study design was successful without the need for further dose escalation beyond 400 mg once daily. In summary, X-82 was well tolerated by most patients, with the most common treatmentrelated grade 3 adverse event (AE) being proteinuria (4%). There were no grade ≥ 4 AEs or deaths thought to be related to X-82. This safety profile is consistent with the mechanism of action. Further improvements in the treatment of advanced cancers with X-82 will likely await identification of and successful combination with other agents. Proportion of patients with stable disease Additional Details of Endpoints or Study Design Additional Notes on Prior Therapy: Dose escalation phase: There was no limit on the amount of prior chemotherapy; dose expansion phase: ≤3 prior cytotoxic treatment regimens, and at least 1 regimen must have included a platinum-containing agent. Dose Escalation Schema: Once-daily dosing regimen used an accelerated titration scheme that evaluated at least one patient per 28-day cycle before escalation to the next dose level. This accelerated titration scheme was to be followed by a 3 + 3 dose escalation (see Protocol Amendment 2). However, based on preliminary PK data from patients in this study, an apparent saturation in absorption of the drug capsule was observed, with a plateau in drug exposure at q.d. doses ≥160 mg. As a result, b.i.d. dosing was employed to further increase exposure and evaluate toxicity (Protocol Amendment 2). A new X-82 tablet formulation was introduced at a starting dose of 50 mg once or twice daily depending on data evaluation from the prior cohort using a 3 + 3 design.
Investigator's Analysis
Active and should be pursued further Response Assessment PR n = 1 (2%)
Response Assessment SD n = 25 (51%)
Response Assessment PD n = 20 (41%)
Response Assessment OTHER n = 2 (4%) Note that two patients experienced a serious adverse event of grade 3 anemia that was unrelated to X-82. In addition, two patients experienced a serious adverse event of grade 3 dyspnea that was unrelated to X-82.
ASSESSMENT, ANALYSIS, AND DISCUSSION

Completion
Study terminated before completion Terminated Reason
Did not fully accrue
Investigator's Assessment Active and should be pursued further Vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) are cell surface tyrosine kinase receptors that represent targets for anticancer therapy in solid tumors. The combined effect on VEGFR and PDGFR with similar potency is thought to contribute to the increased efficacy of sunitinib (SU11248) over other tyrosine kinase inhibitors (TKIs) such as sorafenib, in patients with renal cell carcinoma, that primarily target VEGFR [1] . Vorolanib (X-82) was developed on the same chemical scaffold as sunitinib, targets all isoforms of VEGFR and PDGFR, and was designed to improve the safety profile while maintaining the efficacy of sunitinib.
Clinical studies showed that sunitinib has a long t 1/2 (>40 hours) as well as large distribution and accumulation in various tissues [2] . This observation required sunitinib dosing holidays as reflected in the U.S. Food and Drug Administration-approved dose of 50 mg once daily with 4 weeks on and 2 weeks off (4/2) treatment in metastatic renal cell carcinoma [3] . However, murine pharmacokinetic (PK)/pharmacodynamic (PD) studies of sunitinib suggested that constant inhibition of VEGFR2 and PDGFRβ phosphorylation was not required for efficacy; at highly efficacious doses, inhibition was sustained for 12 hours of a 24-hour dosing interval [4] . With a t 1/2 of about 2 hours in mice, sunitinib displayed intermittent inhibition with daily dosing; however, as the t 1/2 in humans is much longer, daily dosing results in constant inhibition. X-82 was designed to have a short t 1/2 in humans to meet the PK/PD requirement of intermittent inhibition with daily dosing. X-82 was also designed to have a smaller volume of distribution in tissues because its therapeutic targets, VEGFR and PDGFR, are in blood vessels. It was hypothesized that if X-82 had a short t 1/2 and did not accumulate in tissues, it would meet the requirement of intermittent inhibition and minimize the potential for toxicity, while maintaining antitumor activity similar to sunitinib.
The objective of this study was to determine the maximum tolerated dose (MTD) and preliminary PK of single-agent X-82 in patients with advanced solid tumors. The expectation was that an improved safety profile would allow daily dosing of X-82 and permit combination modalities currently precluded by safety concerns with sunitinib. Enrollment was stopped prior to determination of the MTD because of the apparent saturation of absorption at 400-800 mg. We believe that X-82 proved to be less toxic, as proteinuria (two patients, 4%) was the most common treatment-related adverse event reported. Additionally, we considered the intermittent suppression to be clinically effective. In a small phase I/II trial in patients with renal cell carcinoma (about half TKI naïve, half received prior TKI), its efficacy was comparable to other TKIs, but much better tolerated, consistent with the PK/PD model. Finally, the drug sponsor, Xcovery, LLC, has three clinical trials ongoing to investigate the X-82 combination with anti-programmed cell death protein 1 therapies (NCT03511222, NCT03583086, NCT03602547). 
